Repligen Corporation — Q2 2022 Form 10-Q
Business context and reporting period. Repligen develops and sells bioprocessing technologies and systems for biologic drug manufacturing. This unaudited filing covers the three and six months ended June 30, 2022; comparisons are with the corresponding 2021 periods. The company reports as one segment.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $207.6m (+27.4%) | $163.0m | $414.0m (+35.4%) | $305.8m |
| Gross margin | 58.5% | 62.0% | 59.3% | 60.2% |
| Operating income | $63.2m (+30.9%) | $48.2m | $123.2m (+45.5%) | $84.6m |
| Net income | $49.9m (+37.6%) | $36.2m | $96.8m (+47.4%) | $65.7m |
| Diluted EPS | $0.88 | $0.64 | $1.68 | $1.16 |
| Operating cash flow | Not separately stated | Not separately stated | $68.8m | $46.9m |
| Capital expenditures | Not separately stated | Not separately stated | $52.6m | $24.1m |
Q2 operating margin was 30.4%, compared with 29.6% a year earlier; six-month operating margin was 29.7%, compared with 27.7%. Management also reported Q2 adjusted net income of $51.4m, or $0.91 per diluted share, versus $44.9m, or $0.79; six-month adjusted net income was $105.1m, or $1.82 per diluted share, versus $83.6m, or $1.47. These are non-GAAP measures.
Liquidity, debt, and balance sheet
- Cash and cash equivalents were $596.5m at June 30, 2022, down from $603.8m at year-end 2021. Working capital was $552.5m, versus $556.4m.
- Current assets were $976.0m and current liabilities $423.5m (about 2.3x current ratio). Inventories rose to $239.1m from $184.5m.
- Operating cash flow of $68.8m was more than offset by investing outflows of $54.4m, financing outflows of $14.3m, and a $7.4m adverse exchange-rate effect; cash declined $7.3m overall.
- The 0.375% convertible senior notes due July 2024 had a $283.7m net carrying value and were classified as current. Holders could convert during Q3 2022 under the notes’ terms. The company elected to settle principal in cash and any conversion premium in shares.
Changes, outlook, and risks
- Revenue growth reflected strong demand across filtration, chromatography, and process analytics, as well as contributions from acquisitions completed in 2021. Direct sales were 89% of Q2 product revenue, versus 83% a year earlier.
- Gross margin declined as manufacturing headcount and occupancy costs, depreciation, freight, and import duties increased. Cost of product revenue grew faster than revenue.
- A $6.9m Q2 and $9.3m first-half reduction in contingent consideration fair value lowered reported operating expenses. This non-cash valuation adjustment related to Avitide earnouts and reflected changed projections and market inputs.
- Management said R&D expense is expected to increase gradually each quarter for the remainder of 2022 and operating expenses are expected to rise as the business expands. No specific revenue or earnings guidance was provided. Management believed existing cash was adequate for at least 24 months, absent acquisitions or other significant needs.
- Management cited uncertain demand related to COVID-19, supply-chain challenges, inflation and cost pressures, and customer purchasing patterns as factors complicating estimates. It noted that declining vaccination demand may reduce future COVID-related product demand, while demand for cell and gene therapy and monoclonal-antibody manufacturing had increased.
- Other risks include quarterly fluctuations from large production orders and regulatory approvals, acquisition integration and earnout uncertainty, unhedged foreign-exchange exposure, and potential need for financing to fund acquisitions. The filing reported no material changes to the risk factors in the 2021 Form 10-K and no known legal proceedings expected to have a material adverse effect.
- Adoption of ASU 2020-06 on January 1, 2022 changed convertible-note accounting and increased the opening notes’ carrying amount; it also affected reported interest expense and diluted EPS comparisons.
Important facts for investors to verify
- Whether strong product demand persists, particularly as COVID-related demand declines, and how much growth came from acquired businesses.
- Whether inventory buildup and expanded manufacturing capacity convert into sales and cash generation without further gross-margin pressure.
- The timing and potential amount of Avitide contingent consideration payments, whose fair value depends on projected performance and valuation assumptions.
- The implications of the 2024 notes’ current classification, potential conversions, and cash settlement of principal.
- Progress against management’s stated investment plans and the adequacy of liquidity if acquisitions or weaker demand increase funding needs.